DarioHealth Self-test Blood Glucose Meters Can Now Be Utilized Within Hospitals During the COVID-19 Pandemic Per Recently Issued Emergency FDA Guidelines

NEW YORK, May 6, 2020 /PRNewswire/ — DarioHealth Corp. (Nasdaq: DRIO), a global digital therapeutics (DTx) innovator, announced today that in an effort to reduce contact between healthcare providers and patients in hospital settings, limit COVID-19 exposure, and preserve personal protective equipment (PPE), the U.S. Food and Drug Administration (FDA) has recognized that home-use blood glucose meters including Dario’s smartphone-connected metering device may be used by patients with diabetes who are hospitalized due to COVID-19 to check their own blood glucose levels and provide the readings to the health care personnel caring for them.

As a result of these recently updated guidelines, hospitals can now allow patients to self-test using their Dario blood glucose testing strips and smartphone-connected device or the hospital can issue patients a Dario device upon admission to the hospital for COVID-19 related conditions.

This is a critically important development for healthcare workers who will now be able to limit exposure to potentially infected patients and continuously access, monitor, and track blood glucose remotely, without patient contact, through Dario’s provider interface.

Irregularities in blood glucose levels are suspected as a factor in the increased severity of potentially deadly COVID-19 complications, driving a high priority placed on stabilization of patients’ blood glucose levels.

“This common-sense lifting of restrictions on blood glucose monitoring in hospitals has outsized benefit for care providers and patients alike who are actively seeking ways to protect against contracting the deadly virus,” commented Rick Anderson, DarioHealth president, and general manager. “Furthermore, it allows more frequent testing of hospitalized patients which leads to improved blood glucose stabilization.”

About DarioHealth Corp.

DarioHealth Corp. (Nasdaq: DRIO) is a leading global digital health company serving its users with dynamic mobile health solutions. In today’s day and age, knowledge of health and treatment is being democratized, and we believe people deserve to know everything about their own health and have the best tools to manage their condition. DarioHealth employs a revolutionary approach whereby harnessing big data, we have developed a novel method for chronic disease data management, empowering people to analyze and personalize chronic disease management in a totally new way without having their conditions slow them down. DarioHealth has a commercial office in New York, New York with an R&D center in Caesarea, Israel.

For more information, visit http://mydario.investorroom.com/.

Cautionary Note Regarding Forward-Looking Statements

This news release and the statements of representatives and partners of DarioHealth Corp. (the “Company”) related thereto contain or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as “plan,” “project,” “potential,” “seek,” “may,” “will,” “expect,” “believe,” “anticipate,” “intend,” “could,” “estimate,” or “continue” are intended to identify forward-looking statements. For example, Dario is using forward-looking statements in this press release when it discusses the benefits of the lifting of restrictions on blood glucose monitoring in hospitals. Readers are cautioned that certain important factors may affect the Company’s actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company’s results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company’s actual results and forward-looking statements include, but are not limited to, those risks discussed in the Company’s filings with the U.S. Securities and Exchange Commission. Readers are cautioned that actual results (including, without limitation, the timing for and results of the Company’s commercial and regulatory plans for Dario™) may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

DarioHealth Corporate Contact:
Claudia Levi
Content & Communications Manager
claudia@mydario.com   
+1-347-767-4220

Media Inquiries:
Investor Relations Contact:
Matthew Picciano
MPicciano@lifesciadvisors.com 
+1-646-889-1200

View original content to download multimedia:http://www.prnewswire.com/news-releases/dariohealth-self-test-blood-glucose-meters-can-now-be-utilized-within-hospitals-during-the-covid-19-pandemic-per-recently-issued-emergency-fda-guidelines-301053830.html

SOURCE DarioHealth Corp.